Abstract
Ketone body oxidation is often considered an efficient energy source for the heart, yielding more ATP per mole of oxygen than glucose. However, its role during acute ischemic events remains controversial. This study investigates the impact of β-hydroxybutyrate (β-OHB), the primary constituent of ketone bodies, on cardiomyocytes under hypoxic conditions and the consequences of a ketogenic diet (KD) in a myocardial infarction (MI) mouse model. We demonstrate that elevated β-OHB levels exacerbate cardiac damage by suppressing the HIF-1α-mediated glycolytic switch, a critical survival mechanism during oxygen deprivation. Stabilization of HIF-1α via Roxadustat administration partially reversed these harmful effects, suggesting a potential therapeutic target for mitigating ischemic injury.
Introduction
The heart is a metabolic omnivore, primarily relying on fatty acid oxidation for energy under normal conditions. During myocardial infarction (MI), oxygen scarcity forces a shift toward glycolysis—a process that yields less ATP per glucose molecule but requires significantly less oxygen than oxidative phosphorylation. This metabolic adaptation is orchestrated by Hypoxia-Inducible Factor 1α (HIF-1α), which upregulates glucose transporters and glycolytic enzymes to maintain energy production when oxygen is scarce.
Recently, ketone bodies like β-hydroxybutyrate (β-OHB) have gained attention as an efficient alternative fuel, particularly in the context of chronic heart failure. However, their role during acute oxygen deprivation (hypoxia) remains poorly understood. This research explores whether an abundance of ketones during acute ischemia is adaptive or maladaptive, investigating the molecular interplay between β-OHB and the HIF-1α survival pathway.
Methodology
The researchers employed a multi-pronged approach combining clinical data, animal models, and cellular experiments:
- Clinical Correlation: Plasma β-OHB levels were analyzed in 45 acute MI patients and 32 healthy volunteers at Shanxi Cardiovascular Hospital to correlate ketone levels with markers of heart stress (NT-proBNP) and function (LVEF).
- Animal Models: Male C57BL/6 mice (6–8 weeks old) were randomized to either a standard chow diet (CD; 11 kcal% fat, 20 kcal% protein, 69 kcal% carbohydrates) or a ketogenic diet (KD; 93.5 kcal% fat, 4.7 kcal% protein, 1.8 kcal% carbohydrates). After four weeks of dietary intervention, MI was induced via permanent ligation of the left anterior descending (LAD) artery. Mice with post-surgical LVEFs between 30–45% were selected for further experimental analysis.
- In Vitro Hypoxia Models: Isolated mouse primary cardiomyocytes and human AC16 cells were subjected to 1% oxygen (hypoxia) and treated with varying doses of exogenous β-OHB.
- Molecular Analysis: The team used qPCR, Western blotting, and immunofluorescence to track the expression of HIF-1α, its regulatory protein VHL, and glycolytic targets like GLUT1 and LDHA.
- Pharmacological Intervention: Roxadustat, a HIF prolyl hydroxylase inhibitor, was administered to test if stabilizing HIF-1α could mitigate the damage caused by β-OHB.
Results
Clinical and In Vivo Evidence of Maladaptation
Clinical analysis revealed that MI patients had significantly higher plasma β-OHB levels than healthy controls. Crucially, higher β-OHB concentrations were associated with lower ejection fractions and higher NT-proBNP levels, suggesting that elevated ketones are linked to worse outcomes in acute MI.
In the mouse model, those fed a ketogenic diet exhibited significantly higher blood β-OHB levels and suffered more severe cardiac damage post-MI compared to CD-fed mice. The KD group showed an average infarct area of approximately 60%, compared to 50% in the CD group. Furthermore, the LVEF in KD-fed mice dropped to ~25%, while the control group maintained ~35%.
Sabotaging the Metabolic "Lifeboat"
In vitro experiments showed that β-OHB dose-dependently increased cardiomyocyte death under hypoxia, whereas it had no adverse effects under normoxic conditions. Mechanistically, the researchers found that β-OHB accumulation triggers the upregulation of the von Hippel-Lindau (VHL) protein. VHL marks HIF-1α for proteasomal degradation, effectively sabotaging the cell's primary survival mechanism under low oxygen.
Because HIF-1α was suppressed, the cardiomyocytes failed to increase glucose uptake and glycolytic flux. This left the cells energy-starved and more prone to necrotic death. Interestingly, the study also found that the heart's ability to metabolize β-OHB itself was impaired under hypoxia, leading to further intracellular accumulation of the ketone and exacerbating the injury.
Therapeutic Potential of HIF-1α Stabilization
Administering Roxadustat partially reversed the harmful effects of β-OHB. By inhibiting the degradation of HIF-1α, Roxadustat restored the expression of glucose transporters and glycolytic enzymes, shifting the metabolic profile back toward protective glycolysis and reducing cell death.
Discussion and Conclusion
This study highlights a "ketone paradox": an energy source that is efficient under aerobic conditions becomes a liability during acute hypoxia. By destabilizing HIF-1α, β-OHB prevents the necessary shift to glycolysis, leaving cardiomyocytes vulnerable to ischemic injury.
While the findings are robust, the authors note that Roxadustat only provided a partial rescue, suggesting that β-OHB might impair heart cells through additional, yet-to-be-discovered pathways. Furthermore, the exact molecular "sensor" that detects β-OHB and triggers VHL upregulation remains unknown.
In conclusion, elevated β-OHB levels—whether from endogenous production or a ketogenic diet—are maladaptive to the heart under acute hypoxic/ischemic conditions. These findings suggest that a ketogenic diet may be inadvisable for individuals at high risk of myocardial infarction, as it may "add fuel to the fire" of ischemic damage.
Summary updated